Overview

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ranolazine